Profil
Stig K.
Hansen is the founder of Carmot Therapeutics, Inc. (founded in 2008) and currently holds the title of Director.
Dr. Hansen is also the founder of Kimia Therapeutics, Inc...
Postes actifs de Stig Hansen
Sociétés | Poste | Début |
---|---|---|
Carmot Therapeutics, Inc.
Carmot Therapeutics, Inc. BiotechnologyHealth Technology Carmot Therapeutics, Inc. is a clinical-stage biotechnology company, which engages in the development of therapeutics for metabolic diseases, cancer, and inflammation. Its pipeline includes CT-388, CT-996, and CT-868. The CT-388 refers to treatment taken once-weekly subcutaneous injectable for obesity and type 2 diabetes (T2D). The CT-996 comprises of once-daily oral treatment for obesity and T2D. The CT-868 consists of once-daily subcutaneous injectable for treatment of type 1 diabetes (T1D) patients with overweight or obesity. The company was founded in 2008 and is headquartered in Berkeley, CA. | Fondateur | 01/01/2008 |
Kimia Therapeutics, Inc.
Kimia Therapeutics, Inc. BiotechnologyHealth Technology Kimia Therapeutics, Inc. is a drug discovery company that utilizes high throughput precision chemistry, genome editing, and machine learning to identify druggable sites for human disease intervention. The private company is based in Berkeley, CA. The company is building a next-generation therapeutics discovery platform called Atlas, which combines active learning with automated synthesis and screening. Atlas is powered by a high-throughput, nano-liter scale chemistry platform that provides Kimia with instant access to billions of drug-like compounds. The CEO of the company is Stig K. Hansen. | Fondateur | - |
Expériences
Fonctions occupées
Relations
Relations au 1er degré
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
Entreprise privées | 2 |
---|---|
Carmot Therapeutics, Inc.
Carmot Therapeutics, Inc. BiotechnologyHealth Technology Carmot Therapeutics, Inc. is a clinical-stage biotechnology company, which engages in the development of therapeutics for metabolic diseases, cancer, and inflammation. Its pipeline includes CT-388, CT-996, and CT-868. The CT-388 refers to treatment taken once-weekly subcutaneous injectable for obesity and type 2 diabetes (T2D). The CT-996 comprises of once-daily oral treatment for obesity and T2D. The CT-868 consists of once-daily subcutaneous injectable for treatment of type 1 diabetes (T1D) patients with overweight or obesity. The company was founded in 2008 and is headquartered in Berkeley, CA. | Health Technology |
Kimia Therapeutics, Inc.
Kimia Therapeutics, Inc. BiotechnologyHealth Technology Kimia Therapeutics, Inc. is a drug discovery company that utilizes high throughput precision chemistry, genome editing, and machine learning to identify druggable sites for human disease intervention. The private company is based in Berkeley, CA. The company is building a next-generation therapeutics discovery platform called Atlas, which combines active learning with automated synthesis and screening. Atlas is powered by a high-throughput, nano-liter scale chemistry platform that provides Kimia with instant access to billions of drug-like compounds. The CEO of the company is Stig K. Hansen. | Health Technology |